Table 1.

Select Ongoing Trials Involving Immune Checkpoint Inhibitors for GC.

Clinical Trial Information	Immunotherapy Type	Other Therapy	Patient Population	Status
NCT04592913 MATTERHORN Phase III	Neoadjuvant-Adjuvant Durvalumab vs. Adjuvant Durvalumab	Neoadjuvant-Adjuvant FLOT chemotherapy	GC and GEJC	Recruiting
NCT02872116 Checkmate 649, Phase III	Nivolumab Plus Ipilimumab vs. Nivolumab in Combination with chemotherapy vs. chemotherapy alone	Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX) or Oxaliplatin + Capecitabine (XELOX)	Previously untreated advanced or metastatic GC or GEJC	Active, not recruiting
NCT03517488 Phase I	XmAb20717 (monoclonal antibody targeting both PD1 and CTLA-4)	N/A	Multiple tumor types, including GC	Active, not recruiting
NCT04835896 Phase Ib/II	M7824 (Bintrafusp Alfa, dual target anti-TGFβ and PDL-1)	Weekly paclitaxel	Recurrent/metastatic GC	Not yet recruiting
NCT03539822 Phase I/II	Cabozantinib plus Durvalumab (GC cohort)	N/A	Advanced GC, GEJC, others	Recruiting
NCT04164979 Phase II	Cabozantinib Combined with Pembrolizumab	N/A	Metastatic or recurrent GC, GEJC (progressed, or not tolerated, at least one prior line of chemotherapy)	Recruiting
NCT04082364 Phase II/III	Margetuximab Retifanlimab, Tebotelimab, Trastuzumab	XELOX or mFOLFOX6	HER2+ GC or GEJC	Active, not recruiting